FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production
27.9.2019 18:00:00 EEST | Business Wire | Press release
RoboSense, the pioneering Smart LiDAR Sensor provider, announced a partnership with FAW ("First Automobile Works"), the world's leading automotive OEM (Original Equipment Manufacturer), and showcased the milestone achievement of last year’s cooperation: the first batch of world’s first solid-state Smart LiDAR Sensor RS-LiDAR-M1 on September 25. The deal is to include RS-LiDAR-M1 as core component into FAW's proprietary next-generation autonomous driving system development, therefore accelerating the serial production of the world's first automotive-grade solid-state MEMS-based Smart LiDAR Sensor, in order to promote Level 3 vehicle autonomy and above.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190927005229/en/
FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production (Photo: Business Wire)
The final commercialized version of RS-LiDAR-M1 is the world’s first and only all-in-one unit MEMS-based Smart LiDAR Sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC (System of Chip). It transforms traditional LiDAR systems (also known as solely data collectors), to full data analysis and comprehension systems. The RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but its built-in AI algorithm and SoC also process road data in real-time, while at the same time synchronizing outputs of high-precision localization, obstacle detection, tracking and classification, road curbs and driving areas detection.
Unlike RoboSense Smart LiDAR Sensor, when mechanical LiDAR is used on a vehicle, a computer-sized ECU must also be used to operate the algorithms. Compared with ECUs, the RoboSense dedicated SoC built into the Smart LiDAR Sensor not only withstands strong bumps and jolts in the vehicle, but is also small and light-weight. The RoboSense Smart LiDAR Sensor's built-in SoC can largely reduce more power consumption while improving performance compared to automotive ECUs, saving much more passenger space at the same time.
The RS-LiDAR-M1 is cleanly designed in a streamlined body that allows it to be easily embedded onto any part of the vehicle for the complete aesthetics of automobile.
Serial produced RoboSense Smart LiDAR Sensor costs only hundreds of dollars each, based on its deployment of revolutionary MEMS micro-mirror scanning structure and simplified manufacturing and streamlines production, while maintaining high product quality and reliability to meet exacting OEM requirements.
Fengjun Li, Director of Intelligent Connected Vehicle Development Institute, FAW, said, "China is standing at the front of the world's autonomous driving development. Our cooperation with RoboSense demonstrates our confidence in Smart LiDAR Sensor for Level 3 vehicle autonomy and above, and accelerates the commercialized development of our proprietary next-generation autonomous driving system”.
"The RS-LiDAR-M1 is a revolutionary product developed upon more than ten years of research development accumulated by the RoboSense team. We believe the partnership will enhance the serial production ability of automotive-grade Smart LiDAR Sensor for autonomous driving,” said Steven Qiu ChuanXin, RoboSense Founder and CEO.
At the signing ceremony, the closest to commercialized version of Smart LiDAR Sensor RS-LiDAR-M1 delivered by RoboSense will be used for FAW's automotive-grade testing and self-driving passenger cars research development. The current version has greatly improved performance while reducing the size to only the half of the former demo showcased on CES 2019, which can be easily integrated into any part of the vehicle body. More details of the latest version will be coming soon.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the first and only MEMS-based Smart LiDAR Sensor for autonomous driving.
For more information about RoboSense please visit: https://www.robosense.ai/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190927005229/en/
Contact information
Media:
Cassie Gong, PR Manager
sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom